Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|November 17, 2025

Choosing Nontraditional Digital Platforms for Patient Recruitment

Explore which factors—audience relevance, content fit, and engagement quality—determine the best use of platforms like TikTok, Reddit, and Spotify for targeted patient recruitment campaigns.

In a recent video interview with Applied Clinical Trials, Christian Bullock, digital marketing director at Trialbee, discussed strategies for using nontraditional digital platforms to enhance patient recruitment. He outlined three key factors—audience relevance and intent, content fit and creative potential, and quality of engagement—as critical for determining platform suitability. Bullock explained how platforms such as TikTok, Reddit, and Spotify attract distinct demographics and require tailored messaging, creative formats, and calls to action to support multi-touch recruitment funnels. He highlighted operational and compliance challenges on emerging or entertainment-focused platforms, noting the need for ongoing communication with ad policy teams and careful evaluation of platform restrictions. Bullock shared lessons learned from successful campaigns on Spotify, Nextdoor, and other emerging platforms, emphasizing the importance of testing, monitoring both engagement and conversion, and applying a data-driven approach to optimize ROI while maintaining compliance.

The below interview transcript was lightly edited for clarity

ACT: What factors do you consider when choosing which nontraditional digital platforms—like TikTok, Reddit, or Spotify—to use for patient recruitment in a given trial?

Bullock: Sure, there are three specific factors we look at when we're making that determination [to see] if it would fit within a trial’s digital marketing campaign. So the first one is audience, relevance, and intent. We have historical data ourselves firsthand, as well as obviously reaching out and seeing credible third-party resources that show things like user bases per platform and by geography, [which] allows us to [see whether] this platform aligns with the audiences that we're trying to target ads [to], right around a patient and their care partners, demographic information, psychographics, and behavior.

So for instance, we know that TikTok typically caters towards a younger audience, younger caregivers, [and] health-conscious millennials, whereas Reddit skews a little bit more male, or those that identify as male, as well as just having a little bit more of an intentional research and discussion via subreddits, joining subreddits, commenting, and otherwise. So that's audience, relevance, and intent.

Secondly, we also look at content fit and creative potential. We evaluate whether that ad platform’s content formats allow us to serve ads in ways that we want to. We know that some platforms invest heavily in having video ads that may be more storytelling-based or even quick video advertisements. However, we also know that there are platforms on the opposite side of that spectrum—some that really rely on serving static banner ads, or passive kind of consumption, so to speak, during daily routines.

And then, thirdly, we look at [the] importance of quality. We know that nontraditional platforms typically almost always have lower patient and care partner populations for us to get ads in front of—just purely, that's a numbers game. From a volume-based perspective, what our delivery team is curious about is not only the number of potential participants we receive from these nontraditional platforms, but the quality of those [participants]. So just not focusing on a numbers game aspect, but also understanding and knowing that maybe a smaller pond, but we're getting a higher quality of fish, so to speak.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.